EyeCool Therapeutics Announces Encouraging Interim Clinical Results for ETX-4143 in Chronic Ocular Surface Pain
BOSTON, MA, UNITED STATES, January 8, 2026 /EINPresswire.com/ -- EyeCool Therapeutics, a clinical-stage ophthalmic medical device company, today announced encouraging interim results from its ongoing ETX4143-A005 clinical study being conducted at the …